RecruitingPhase 2NCT07746180

Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis: A Prospective Exploratory Study

Sponsor

Chinese PLA General Hospital

Enrollment

20 participants

Start Date

Aug 21, 2026

Study Type

INTERVENTIONAL

Conditions

ANCA Associated Vasculitis (AAV)ANCA-Associated Glomerulonephritis (AAGN)

Summary

This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Glucocorticoids and a drug called Obinutuzumab beta for people with anca associated vasculitis (aav) and anca-associated glomerulonephritis (aagn). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGObinutuzumab beta

Intravenous infusion of Obinutuzumab beta administered during the induction phase.

DRUGGlucocorticoids

Oral glucocorticoid induction starting alongside Obinutuzumab beta, following a prespecified rapid tapering schedule aimed at complete discontinuation by Week 24.